Q1 2020 Earnings Call - Second

You bet Conferencing center colds may be recorded for the purpose of quality and training. Please enter your event plus passcode followed by the hash sign.

Okay.

Yes.

Okay.

Oh.

Oh.

After the tone. Please clearly statin spell your first and last name and company name followed by the hash key.

David Brown, the JV I'd be are all double yen for all IRA A.I.E.R.A.

And then when you have been running off the cells.

Are you the sales of dying that is quite often replaced by fibrous tissue. So so and the reason why I can say this we have very nice effects on building in this trial with very significant reductions in cell death in the biopsies and when I then look.

At the fibrosis Marcus in the else biomarker panel, but also in the Elastography fibers game, we're actually seeing that those fibrosis parameters come down dose dependently. So so for me the cirrhotic phenotype is typically.

A consequence of that this metabolism and inflammation that that drives the disease than the fibrosis is the end outcome you might have patients that are more prone to two fibrosis, even that lever lower levels of tier two hepatitis, but I don't have much prove to the putting from this trial and.

Then on the oral yes. It is true we're doing these new generation you a waste of formulating rebels was in a smarter way.

And those trials ongoing.

They might be a bit delayed because they are ongoing trials and of course. These early stage trials and you know that phase one like trials a more hurt by the code 900 situation, but then again we have ever built is on the market and we are we're not a desperate for having a new formulation of reversal market, even though we'd like to habit.

Of course for obvious reasons.

Can I just like one alone for Camilla.

Thanks for that color on and they are actually it's your age and what are you seeing in terms of realized discontinuation rates versus what was in the label.

It's too early for us to say anything on that at this point in time, so and we would have to see sort of the.

Continued uptake of rebel first of all we can say that way to reasonable patient number.

We don't see any signals that there are any issues on this we got so we don't have any asset quality instead of feedback on that.

Thank you.

Thank you.

One last question comes from the line as Michael Luncheon from.

Your line is now.

Thank you for final question, So just talking about risk management Warner if youre.

Big driver of softer returns has been your ability to be extremely efficient on the manufacturing side, which obviously includes the yield improvement that matchless was referring to.

As we now goes through to pandemic is turned argument that you may have to decentralize manufacturing process to to be able to stop potential disruption that a pandemic such as we are experiencing now might bring to manufacturing side or are you able to manage this any.

Mines with a set up you have maybe watches segmenting existing facilities. Thank you.

Thank you Michael it's it's a very relevant question that the that.

We of course ask yourself as part of the learnings from a corporate 19 and the in related it's a question that we've been discussing with our board for for an obvious.

As part of general risk management and.

And we have a review of the biggest risks for the company across the value chain.

And.

I'd say in conclusion, when you look at our manufacturing and if I, if I take kind of the the value chain. In manufacturing. Then then for on our supply base then for our critical supplies of of the various raw materials. We are very focused on having dual sourcing.

From a different manufacturers are off from different geographies.

For the critical raw materials in manufacturing if for some reason that is not the case. Then then for those few raw materials. Then we said inventory policies that that are.

Very very high. So then we could have perhaps six or 12 are even more months worth of raw material on inventory.

Then in terms of our in house manufacturing, if we move through the value chain in AI.

This is basically a key part of our epi manufacturing that now we have our diabetes CPI facility soon to be up and running within the next day Yeso in North Carolina. So so actually we have.

At better hedged than ever before on insulin API on top of the.

Inventory policies, we have that are between I would say nine and 24 months on a pie.

Hey.

Biopharm, we also have facility in the US now in New Hampshire for some of the biopharm products apart from the inventory levels.

And then finally on on the finished goods manufacturing, we have filling factories in France in China in Brazil in the U.S. and in Denmark.

And then a few others, so and there were securing tool approvals for products. So so for instance, when.

In China close down early in the year, then we had other finished goods.

Facilities that could stebenne and supply Margaret said that the attention could not supply. So I don't foresee any significant change to our global manufacturing network.

Moving from Cobas 19, but that said of course, our other learning center that will take into our into account.

So so with that thank.

Thank you for attending the EWP, yes virtual.

No Norsk Q1.

Roadshow and thank you for the interest in our company and if you have further questions. Please do not hesitate to reach out to Investor Relations and we'll get get back to swiftly. So have a good rest of today and as they say safe out there. Thank you.

Ladies and gentlemen that does conclude your conference for today. Thank you for participation you may now disconnect. Thank you.

[music].

[music].

[music].

[music].